Sign in

Andrea Park

Research Analyst at Leerink Partners

Andrea Park is currently Director of Business Development and M&A Analytics at BeiGene, specializing in transaction analysis and corporate development within the biopharmaceutical sector. She covers companies in the oncology and pharmaceutical fields, leveraging her expertise to support high-value strategic deals and partnerships. Andrea began her professional journey in healthcare finance and analytics, progressing through various analytical and strategic roles before joining BeiGene, where she has contributed to multiple transactions and deal evaluations. She is professionally credentialed in financial analysis, with experience in due diligence and transaction execution for major healthcare organizations.

Andrea Park's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership

Andrea Park's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership • Q2 2025

Question

Andrea Park, on behalf of Joseph Schwartz at Leerink Partners, questioned how BioMarin anticipates VOXZOGO discontinuation rates might change in a future competitive environment with weekly or oral options available.

Answer

Cristin Hubbard, EVP and Chief Commercial Officer, emphasized that current adherence rates for daily VOXZOGO are very high globally, supported by robust patient support programs. She noted that ensuring patients remain on therapy for long-term outcomes is a core strength for BioMarin, and they will continue to invest in initiatives to maintain high compliance.

Ask Fintool Equity Research AI

Andrea Park's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership • Q2 2025

Question

Andrea Park, on behalf of Joseph Schwartz at Leerink Partners, questioned how predictive VOXZOGO's current low discontinuation rates are and how these rates might change with the introduction of competitors.

Answer

Cristin Hubbard, EVP and Chief Commercial Officer, stated that the vast majority of children on VOXZOGO adhere to daily dosing, supported by robust patient support programs, which is a core strength for BioMarin. She emphasized the company's focus on finding, starting, and keeping patients on therapy to ensure the best long-term outcomes, a strategy that will continue regardless of the competitive landscape.

Ask Fintool Equity Research AI